Sign in now to see personalised content appear here.

You can also see your reading history and subscription details on your subscriber page.

Why subscribe?
Find out more.

Sign up for your FREE email newsletter  +


Further reaction to the EU referendum result

Comments from British Generic Manufacturers Association and the British Biosimilars Association, and APBI

Europe | Regulatory | R and D | Generics

Canada opens innovative lab for T cell therapy

New approach to cancer therapy pioneered in new lab in Victoria, British Columbia

North America | Therapeutic Sector

Serialisation: the winding road to implementation

The need for pharmaceutical serialisation is universally acknowledged but has led to a proliferation of national schemes with no global standardisation; Essentra Packaging looks at why serialisation is only part of the solution to counterfeiting challenges

Packaging | Regulatory

Brexit leaves Britain under-skilled, says scientific recruitment expert

The implications that are going arise from the UK leaving the European Union are vast and wide ranging

Europe | Biotechnology

BIA responds to EU referendum vote

BIA remains committed to making the UK the third global cluster for life sciences

Europe | Regulatory | R and D

Paperless pharma: turbocharging development and production

Alwyn Jones, Head of Pharmaceutical and Life Sciences, Siemens UK & Ireland, highlights the company’s new solution for paperless pharmaceutical production that boosts efficiency and makes it easier to introduce personalised cancer therapies, for example

Regulatory | R and D | Information Technology

Oxford Immunotec enters into definitive agreement to acquire Imugen

Acquisition of Imugen is expected to contribute approximately $5.5m in revenue during the second half of 2016

R and D | Therapeutic Sector | Finance | Infections

Handling highly potent materials safely

Choosing a partner to manufacture potent or highly potent materials requires more consideration than a normal CMO partnership, reports Karolina Narczykiewicz, Operations EHS Manager, Catalent

Ingredients | R and D

Cobra Biologics and Alligator Bioscience extend drug development partnership

Project will deliver second cell line to manufacture immuno-oncology antibody ADC-1015 following ADC-1013 success

Ingredients | R and D | Therapeutic Sector

Validation of disinfection protocols

Regulatory agencies require evidence that disinfection procedures used in pharma cleanrooms are effective and while disinfectants qualified by the vendor, it is also necessary to prove their performance is adequate in a real use scenario. Dr Axel Wehrmann, SGS Life Sciences, outlines the process­

Cleaning | Measurement and Analysis

RSA Group publishes new study on leadership in digital health

Research spotlights increases in funding and recruitment

R and D | Finance

The evaluation and safe handling of ADCs and their toxic payloads: Part 1

The handling of ADCs in R&D and manufacturing requires careful examination of the potential health effects that may be caused by occupational exposure. In this first article of a two-part series, John Farris and Robert Sussman, SafeBridge Consultants, discuss the toxicology of ADCs

In the Press